Pakistan to treat Covid with Chinese herbal medicines


The trials, approved by the DRAP, were carried out on 300 patients treated at home, the ICCBS director said.


Pakistani health authorities on Monday announced the completion of a successful clinical trial of traditional Chinese herbal medicine for the treatment of Covid-19, as the South Asian nation enters a fifth wave of the pandemic caused by the Omicron variant.

The Chinese drug, Jinhua Qinggan Granules (JHQG) manufactured by Juxiechang (Beijing) Pharmaceutical Co Ltd, is already being used in the treatment of Covid-19 patients in China.

“Since it has been tried on patients with different variants of Covid-19, we expect it to be effective on Omicron as on other variants,” said Professor Iqbal Chaudhry, director of the International Center for Chemical and Biological Sciences (ICCBS) where trials were conducted. , told reporters.

The trials were conducted on 300 patients treated at home and would work on mild to moderate cases of Covid-19, Dr Raza Shah, the trials’ principal investigator, told reporters, adding that the effectiveness rate was around 82.67%.

The trials have been approved by the Pakistan Drug Regulatory Authority.

Pakistan reported 4,340 cases of Covid-19 on Monday, the highest recorded over a 24-hour period in three months.

Karachi, the country’s largest city, recorded a positivity rate – the percentage of tests coming back positive – of 39.39% over the weekend, the highest yet.


Comments are closed.